Drug Profile
Research programme: B-RAF kinase inhibitors - Aravive
Alternative Names: B-seriesLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Ruga Corporation; Selexagen Therapeutics
- Developer Aravive Biologics
- Class
- Mechanism of Action Mitogen-activated protein kinase inhibitors; Proto oncogene protein b raf inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer